414 related articles for article (PubMed ID: 25779572)
21. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
Hecke SV; Calcoen B; Lagrou K; Maertens J
Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
[TBL] [Abstract][Full Text] [Related]
22. Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity.
Hahn F; Hutterer C; Henry C; Hamilton ST; Strojan H; Kraut A; Schulte U; Schütz M; Kohrt S; Wangen C; Pfizer J; Couté Y; Rawlinson WD; Strobl S; Marschall M
Antiviral Res; 2018 Nov; 159():84-94. PubMed ID: 30268914
[TBL] [Abstract][Full Text] [Related]
23. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses.
Marschall M; Stamminger T; Urban A; Wildum S; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2012 Feb; 56(2):1135-7. PubMed ID: 22106211
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.
Chou S
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827420
[TBL] [Abstract][Full Text] [Related]
25. Investigational Antiviral Therapy Models for the Prevention and Treatment of Congenital Cytomegalovirus Infection during Pregnancy.
Hamilton ST; Marschall M; Rawlinson WD
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077661
[TBL] [Abstract][Full Text] [Related]
26. Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus.
Oiknine-Djian E; Bar-On S; Laskov I; Lantsberg D; Haynes RK; Panet A; Wolf DG
Antiviral Res; 2019 Dec; 172():104639. PubMed ID: 31654672
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.
Piret J; Goyette N; Boivin G
Antiviral Res; 2022 Jun; 202():105328. PubMed ID: 35490740
[TBL] [Abstract][Full Text] [Related]
28. Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.
Santos Bravo M; Tilloy V; Plault N; Palomino SS; Mosquera MM; Navarro Gabriel M; Fernández Avilés F; Suárez Lledó M; Rovira M; Moreno A; Linares L; Bodro M; Hantz S; Alain S; Marcos MÁ
Microbiol Spectr; 2022 Apr; 10(2):e0019122. PubMed ID: 35343771
[No Abstract] [Full Text] [Related]
29. New therapies for human cytomegalovirus infections.
Britt WJ; Prichard MN
Antiviral Res; 2018 Nov; 159():153-174. PubMed ID: 30227153
[TBL] [Abstract][Full Text] [Related]
30. The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors.
Hutterer C; Hamilton S; Steingruber M; Zeitträger I; Bahsi H; Thuma N; Naing Z; Örfi Z; Örfi L; Socher E; Sticht H; Rawlinson W; Chou S; Haupt VJ; Marschall M
Antiviral Res; 2016 Oct; 134():130-143. PubMed ID: 27515131
[TBL] [Abstract][Full Text] [Related]
31. Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.
Turner N; Strand A; Grewal DS; Cox G; Arif S; Baker AW; Maziarz EK; Saullo JH; Wolfe CR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642941
[TBL] [Abstract][Full Text] [Related]
32. Small Molecules-Prospective Novel HCMV Inhibitors.
Bogner E; Egorova A; Makarov V
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809292
[TBL] [Abstract][Full Text] [Related]
33. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
Cho JC; Le AD; Locke SC
Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
[TBL] [Abstract][Full Text] [Related]
34. Anticytomegalovirus Peptides Point to New Insights for CMV Entry Mechanisms and the Limitations of
Jackson JW; Hancock TJ; Dogra P; Patel R; Arav-Boger R; Williams AD; Kennel SJ; Wall JS; Sparer TE
mSphere; 2019 Feb; 4(1):. PubMed ID: 30760613
[TBL] [Abstract][Full Text] [Related]
35. Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus.
Melendez DP; Razonable RR
Infect Drug Resist; 2015; 8():269-77. PubMed ID: 26345608
[TBL] [Abstract][Full Text] [Related]
36. Thioxothiazolo[3,4-a]quinazoline derivatives inhibit the human cytomegalovirus alkaline nuclease.
Zhang T; Potgieter TI; Kosche E; Rückert J; Ostermann E; Schulz T; Empting M; Brune W
Antiviral Res; 2023 Sep; 217():105696. PubMed ID: 37541625
[TBL] [Abstract][Full Text] [Related]
37. New Insights into Human Cytomegalovirus pUL52 Structure.
Muller C; Alain S; Gourin C; Baumert TF; Ligat G; Hantz S
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452502
[TBL] [Abstract][Full Text] [Related]
38. Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives.
Mercorelli B; Lembo D; Palù G; Loregian A
Pharmacol Ther; 2011 Sep; 131(3):309-29. PubMed ID: 21570424
[TBL] [Abstract][Full Text] [Related]
39. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.
Herget T; Freitag M; Morbitzer M; Kupfer R; Stamminger T; Marschall M
Antimicrob Agents Chemother; 2004 Nov; 48(11):4154-62. PubMed ID: 15504835
[TBL] [Abstract][Full Text] [Related]
40. A Novel Triple-Fluorescent HCMV Strain Reveals Gene Expression Dynamics and Anti-Herpesviral Drug Mechanisms.
Rand U; Kubsch T; Kasmapour B; Cicin-Sain L
Front Cell Infect Microbiol; 2020; 10():536150. PubMed ID: 33489928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
